Judith Kannenberg1, Henning Trawinski2, Reinhard Henschler3, Raymund Buhmann3, Mario Hönemann1, Christian Jassoy1. 1. Institute for Medical Microbiology and Virology, University Hospital and Medical Faculty, University of Leipzig, Leipzig, Germany. 2. Division of Infectious Diseases and Tropical Medicine, Department of Medicine II, University Hospital and Medical Faculty, University of Leipzig, Leipzig, Germany. 3. Institute of Transfusion Medicine, University Hospital and Medical Faculty, University of Leipzig, Leipzig, Germany.
Abstract
BACKGROUND: The possibility of repeat infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) raises questions regarding quality and longevity of the virus-induced immune response. METHODS: The antibody course and memory B-cell (MBC) response against SARS-CoV-2 proteins, influenza virus nucleoprotein (NP), and tetanus toxin were examined in adults with mild to moderate SARS-CoV-2 infection in the first year after infection. RESULTS: The concentration of SARS-CoV-2 receptor binding domain (RBD)-specific antibodies was low compared with the concentration of influenza virus NP-specific antibodies. The SARS-CoV-2 RBD antibody half-life increased from 95 days in the first 6 months to 781 days after 9-12 months. The SARS-CoV-2 NP antibody half-life increased from 88 to 248 days. Two thirds of the subjects had SARS-CoV-2-specific MBC responses 12 months after infection. The SARS-CoV-2 antibody levels correlated with the MBC frequency at 12 months. CONCLUSIONS: The low concentration of SARS-CoV-2 spike protein antibodies indicates that re-exposure to the virus or vaccination are required to use the B-cell immunity to full capacity. The existence of a robust SARS-CoV-2 MBC response at 12 months in most subjects and the substantially increasing antibody half-life provide evidence that the immune response is developing into long-term immunity. The early antibody reaction and the ensuing MBC response are interdependent.
BACKGROUND: The possibility of repeat infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) raises questions regarding quality and longevity of the virus-induced immune response. METHODS: The antibody course and memory B-cell (MBC) response against SARS-CoV-2 proteins, influenza virus nucleoprotein (NP), and tetanus toxin were examined in adults with mild to moderate SARS-CoV-2 infection in the first year after infection. RESULTS: The concentration of SARS-CoV-2 receptor binding domain (RBD)-specific antibodies was low compared with the concentration of influenza virus NP-specific antibodies. The SARS-CoV-2 RBD antibody half-life increased from 95 days in the first 6 months to 781 days after 9-12 months. The SARS-CoV-2 NP antibody half-life increased from 88 to 248 days. Two thirds of the subjects had SARS-CoV-2-specific MBC responses 12 months after infection. The SARS-CoV-2 antibody levels correlated with the MBC frequency at 12 months. CONCLUSIONS: The low concentration of SARS-CoV-2 spike protein antibodies indicates that re-exposure to the virus or vaccination are required to use the B-cell immunity to full capacity. The existence of a robust SARS-CoV-2 MBC response at 12 months in most subjects and the substantially increasing antibody half-life provide evidence that the immune response is developing into long-term immunity. The early antibody reaction and the ensuing MBC response are interdependent.
Authors: Zion Congrave-Wilson; Wesley A Cheng; Yesun Lee; Stephanie Perez; Lauren Turner; Carolyn Jennifer Marentes Ruiz; Shirley Mendieta; Adam Skura; Jaycee Jumarang; Jennifer Del Valle; John Kubale; Emma Kaitlynn Allen; Paul G Thomas; Aubree Gordon; Pia S Pannaraj Journal: Vaccines (Basel) Date: 2022-05-20
Authors: Thomas Lehrnbecher; Ulrich Sack; Carsten Speckmann; Andreas H Groll; Andreas Boldt; Benjamin Siebald; Simone Hettmer; Eva Maria Demmerath; Barbara Schenk; Sandra Ciesek; Jan Henning Klusmann; Christian Jassoy; Sebastian Hoehl Journal: Clin Infect Dis Date: 2022-07-28 Impact factor: 20.999
Authors: Jasper de Boer; Ursula Saade; Elodie Granjon; Sophie Trouillet-Assant; Carla Saade; Hans Pottel; Maan Zrein Journal: PLoS One Date: 2022-09-29 Impact factor: 3.752